Patheon CEO Wes Wheeler said that the alliance would lend the firm’s service offering greater flexibility and improve its access to the lucrative Indian contract manufacturing market.
“With Kemwell's GMP facility and expertise, we can offer our clients low volume, low cost solutions in solid, semi-solid and liquid dosage form manufacturing, and a full range of formulation and CMC-related development services from a new base in India,” Wheeler explained.
Kemwell’s vice president of development Anurag Bagaria echoed Wheeler’s thoughts, commenting that: “Patheon's aseptic and high-potentcy manufacturing expertise brings an important capability to Kemwell's portfolio of services."